Osivax

Lyon, France

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.

$10.5M raised

Mar 2025

Series B

Biotechnology Clinical Trials Health Care

Top Investors

Bpifrance Bill & Melinda Gates Foundation European Innovation Council National Institute of Allergy and Infectious Diseases Anaxago

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Osivax

How much funding has Osivax raised?

Osivax has raised $10.5M in total funding. The most recent round was Series B. The last funding was announced in March 2025.

Who are Osivax's investors?

Osivax's investors include Bpifrance, Bill & Melinda Gates Foundation, European Innovation Council, National Institute of Allergy and Infectious Diseases, Anaxago.

Where is Osivax headquartered?

Osivax is headquartered in Lyon, France.

What does Osivax do?

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.

What stage is Osivax at?

Osivax is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 4, 2025.

MLA

"Osivax — Funding & Investors." VCBacked, March 4, 2025, https://www.vcbacked.co/company/osivax. Accessed July 2, 2026.

APA

VCBacked. (2025). Osivax — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/osivax

Wikipedia (cite web)

{{cite web |title=Osivax — Funding & Investors |url=https://www.vcbacked.co/company/osivax |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 4, 2025.

Similar Companies in Biotechnology

View all

Allterum Therapeutics

Houston$1.0M

Renaissance BioScience

Advanced Microbiome Interventions

Amsterdam$300K